# Phase 2 Fallopian Tube cancer trials recruiting: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials in phase 2 for Fallopian Tube cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Fallopian Tube cancer trials: 37 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/fallopian-tube-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 37
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931313 | PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer | Shanghai Gynecologic Oncology Group | Phase 2 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931313) |
| September 28, 2026 | NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843303) |
| September 11, 2026 | NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | University of Colorado, Denver | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815704) |
| May 18, 2026 | NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591831) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| March 27, 2026 | NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | University of Washington | Phase 2 | Recruiting | Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495124) |
| March 24, 2026 | NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489300) |
| February 25, 2026 | NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432594) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| December 5, 2025 | NCT07265739 | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer | Massachusetts General Hospital | Phase 2 | Not yet recruiting | Platinum Resistant Ovarian Cancer | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265739) |
| June 30, 2025 | NCT07044349 | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal... | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044349) |
| June 17, 2025 | NCT07024784 | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous... | AbbVie | Phase 2 | Recruiting | Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC) | 377 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024784) |
| June 17, 2025 | NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer | The University of Hong Kong | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023484) |
| June 15, 2025 | NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer | The University of Hong Kong | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022535) |
| April 2, 2025 | NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Corcept Therapeutics | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06906341) |
| March 24, 2025 | NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly... | AbbVie | Phase 2 | Recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890338) |
| January 22, 2025 | NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 397 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06787612) |
| December 16, 2024 | NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | Qilu Hospital of Shandong University | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735326) |
| November 12, 2024 | NCT06682988 | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial... | AbbVie | Phase 2 | Recruiting | Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06682988) |
| July 9, 2024 | NCT06492070 | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | Emory University | Phase 2 | Recruiting | Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492070) |
| May 20, 2024 | NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06420973) |
| March 4, 2024 | NCT06290193 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Ovarian Cancer Stage IIIC, Fallopian... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06290193) |
| October 2, 2023 | NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | Sun Yat-sen University | Phase 2 | Not yet recruiting | Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06063070) |
| August 28, 2023 | NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | Hansoh BioMedical R&D Company | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06014190) |
| June 5, 2023 | NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | University of Colorado, Denver | Phase 2 | Recruiting | Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05887609) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 3 |
| Shanghai Gynecologic Oncology Group | 3 |
| The University of Hong Kong | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Roswell Park Cancer Institute | 2 |
| University of Colorado, Denver | 2 |
| Mayo Clinic | 1 |
| Qilu Hospital of Shandong University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| [Corcept Therapeutics](https://specstream.ai/data/clinical-trials/company/corcept-therapeutics) | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Beijing Biostar Pharmaceuticals Co., Ltd. | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| Sun Yat-sen University | 1 |
| University of Washington | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| Fore Biotherapeutics | 1 |
| National Cancer Institute (NCI) | 1 |
| University College, London | 1 |
| North Eastern German Society of Gynaecological Oncology | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Emory University | 1 |
| Peking University Third Hospital | 1 |
| Massachusetts General Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| China | 12 |
| South Korea | 4 |
| Spain | 4 |
| Belgium | 3 |
| France | 3 |
| United Kingdom | 3 |
| Germany | 3 |
| Italy | 3 |
| Hong Kong | 2 |
| Australia | 2 |
| Poland | 2 |
| Canada | 2 |
| Israel | 1 |
| Japan | 1 |
| Taiwan | 1 |
| Turkey (Türkiye) | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Sweden | 1 |
| Puerto Rico | 1 |
| Austria | 1 |
| Czechia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [Education services in the United States](https://specstream.ai/data/businesses/education-services/united-states)
- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
